Cross NC - Search Results

1

Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR.

Emig M, Saussele S, Wittor H, Weisser A, Reiter A, Willer A, Berger U, Hehlmann R, Cross NC, Hochhaus A. Emig M, et al. Among authors: cross nc. Leukemia. 1999 Nov;13(11):1825-32. doi: 10.1038/sj.leu.2401566. Leukemia. 1999. PMID: 10557058

2

Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-alpha.

Hochhaus A, Lin F, Reiter A, Skladny H, van Rhee F, Shepherd PC, Allan NC, Hehlmann R, Goldman JM, Cross NC. Hochhaus A, et al. Among authors: cross nc. Br J Haematol. 1995 Sep;91(1):126-31. doi: 10.1111/j.1365-2141.1995.tb05257.x. Br J Haematol. 1995. PMID: 7577619

3

Quantification of residual disease in Philadelphia-positive acute lymphoblastic leukemia: comparison of blood and bone marrow.

van Rhee F, Marks DI, Lin F, Szydlo RM, Hochhaus A, Treleaven J, Delord C, Cross NC, Goldman JM. van Rhee F, et al. Among authors: cross nc. Leukemia. 1995 Feb;9(2):329-35. Leukemia. 1995. PMID: 7869772

4

Minimal residual disease after bone marrow transplant for chronic myeloid leukaemia detected by the polymerase chain reaction.

Cross NC, Feng L, Bungey J, Goldman JM. Cross NC, et al. Leuk Lymphoma. 1993;11 Suppl 1:39-43. doi: 10.3109/10428199309047861. Leuk Lymphoma. 1993. PMID: 8251914

5

An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders.

Cross NC, Melo JV, Feng L, Goldman JM. Cross NC, et al. Leukemia. 1994 Jan;8(1):186-9. Leukemia. 1994. PMID: 8289486

6

Molecular evidence of minimal residual disease after treatment for leukaemia and lymphoma: an updated meeting report and review.

Potter MN, Cross NC, van Dongen JJ, Saglio G, Oakhill A, Bartram CR, Goldman JM. Potter MN, et al. Among authors: cross nc. Leukemia. 1993 Aug;7(8):1302-14. Leukemia. 1993. PMID: 8350633 Review.

7

Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction.

Hochhaus A, Lin F, Reiter A, Skladny H, Mason PJ, van Rhee F, Shepherd PC, Allan NC, Hehlmann R, Goldman JM, Cross NC. Hochhaus A, et al. Among authors: cross nc. Blood. 1996 Feb 15;87(4):1549-55. Blood. 1996. PMID: 8608246 Free article.

8

Mutational analysis of the p15 and p16 genes in acute leukaemias.

Sill H, Aguiar RC, Schmidt H, Hochhaus A, Goldman JM, Cross NC. Sill H, et al. Among authors: cross nc. Br J Haematol. 1996 Mar;92(3):681-3. doi: 10.1046/j.1365-2141.1996.340858.x. Br J Haematol. 1996. PMID: 8616035

9

p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias.

van Rhee F, Hochhaus A, Lin F, Melo JV, Goldman JM, Cross NC. van Rhee F, et al. Among authors: cross nc. Blood. 1996 Jun 15;87(12):5213-7. Blood. 1996. PMID: 8652835 Free article.

10

Reverse transcription/polymerase chain reaction (RT/PCR) amplification of very small numbers of transcripts: the risk in misinterpreting negative results.

Melo JV, Yan XH, Diamond J, Lin F, Cross NC, Goldman JM. Melo JV, et al. Among authors: cross nc. Leukemia. 1996 Jul;10(7):1217-21. Leukemia. 1996. PMID: 8684005

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

413 results

Search Page

Filters